Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection
February 23, 2021 07:30 ET
|
Adaptive Biotechnologies
T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) Patients can conveniently opt to visit one of nearly 2,000 Labcorp sites or...
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
February 02, 2021 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
January 11, 2021 16:01 ET
|
Adaptive Biotechnologies
Multi-year, pan-portfolio deal extends Adaptive’s proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology This transaction highlights the value of immune receptor data...
Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 30, 2020 16:30 ET
|
Adaptive Biotechnologies
SEATTLE, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
December 06, 2020 10:00 ET
|
Adaptive Biotechnologies
SEATTLE, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
November 23, 2020 08:00 ET
|
Adaptive Biotechnologies
Studies reinforce clonoSEQ as standard of care in minimal residual disease (MRD) across eight disease statesReal-world evidence shows treatment decisions based on precise MRD measurement directly...
Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections
November 13, 2020 08:00 ET
|
Adaptive Biotechnologies
– Findings support upcoming launch of T-Detect™ COVID, first T-cell test for novel coronavirus– Data support mounting evidence that measuring T-cells is necessary to fully characterize immune...
Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio
November 10, 2020 16:13 ET
|
Adaptive Biotechnologies
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results
November 10, 2020 16:10 ET
|
Adaptive Biotechnologies
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020
October 13, 2020 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...